Review
Nature Reviews Cancer 3, 821-831 (November 2003) | doi:10.1038/nrc1211
Aromatase inhibitors for breast cancer: lessons from the laboratory
Stephen R.D. Johnston1 & Mitch Dowsett2 About the authors
Abstract
Endocrine therapy with tamoxifen has been the mainstay of treatment for hormone-sensitive breast cancer for more than 20 years. An alternative strategy of oestrogen deprivation in postmenopausal women with aromatase inhibitors is set to replace tamoxifen based on better efficacy and a delay in the emergence of endocrine resistance. There are fundamental differences in how tamoxifen and aromatase inhibitors alter oestrogen-receptor signalling. Understanding the response and resistance to these different therapies is central to further improving therapeutic options for women with breast cancer.
- View At a Glance
Author affiliations
- Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK.
-
Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK.
Email: mitch.dowsett@icr.ac.uk
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE RESEARCH |
